Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada. … Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.

  2. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … [L17040] Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases.

  3. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalProducts: BEXTRA (R) 40 MG TABLETAS RECUBIERTAS
  4. Drug

    Pirlindole

    go.drugbank.com/drugs/DB09244
    Experimental

    Pirlindole is a selective, reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in several European and non-European countries for the treatment of major depression. … Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug.

    Synonyms: 2,3,3a,4,5,6-Hexahydro-8-methyl-1H-pyrazino(3,2,1-jk)carbazoleCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]

  6. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470]. … It was also previously approved in the United States with orphan drug designation [L1469].

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  7. Drug

    Levorphanol

    go.drugbank.com/drugs/DB00854
    Approved

    It is nearly as effective orally as by injection.

    Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

  9. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  10. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions

    Synonyms: (RS)-OxazepamInternational brands: Ox-Pam